Please provide your email address to receive an email when new articles are posted on . In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into the interleukin-23 inhibitor ...

Guselkumab shows early and durable improvement in joint symptoms, spinal pain, and skin clearance through 2 years in biologic-naive patients with active psoriatic arthritis (PsA), with a considerable ...

Please provide your email address to receive an email when new articles are posted on . Guselkumab 200 mg every 4 weeks was more beneficial in patients with high disease activity and severity than 100 ...

Patients experienced clinically meaningful improvements in health-related quality of life (HRQoL) factors after 6 months of guselkumab, according to one study. Patients with treatment-resistant ...

This new study confirms the noninferiority of extended dosing intervals for psoriasis control in super responders. Guselkumab administered every 16 weeks can maintain disease control in patients with ...

New York, NY — July 17, 2025 — In a major advance for patients with Crohn’s disease, a new study led by researchers at Mount Sinai Health System found that guselkumab, a medication with a mechanism of ...

In the VISIBLE trial, guselkumab led to significant and sustained improvements in scalp psoriasis severity and quality of life in patients with skin of color through 48 weeks. Researchers evaluated ...

*The as observed analysis set included participants who entered the LTE, received ≥1 partial or complete study drug dose during the LTE, remained on treatment, and had data available at Week 96; ...

TREMFYA ® is the only IL-23i to demonstrate clinical remission and endoscopic response, both at one year, with a fully subcutaneous induction regimen Supported by data from the GALAXI study, TREMFYA ® ...